<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2022-21-1-67-73</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1463</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРАКТИЧЕСКИЕ АСПЕКТЫ ЭПИДЕМИОЛОГИИ И ВАКЦИНОПРОФИЛАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRACTICAL ASPECTS OF EPIDEMIOLOGY AND VACCINE PREVENTION</subject></subj-group></article-categories><title-group><article-title>Оценка профилактической эффективности и безопасности азоксимера бромида у медицинских работников, находящихся в контакте с пациентами, госпитализированными по поводу COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of the Preventive Efficacy and Safety of Azoximer Bromide in Healthcare Workers in Contact with Patients Hospitalized for COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9294-7346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Касьяненко</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasyanenko</surname><given-names>K V</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кристина Валерьевна Касьяненко – преподаватель кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний)</p><p>+7 (911) 262-06-33</p></bio><bio xml:lang="en"><p>Kristina V. Kasyanenko – lecturer at the department of infectious diseases </p><p>St. Petersburg</p><p>+7-911-262-06-33</p></bio><email xlink:type="simple">dr.snegur@gmial.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6286-9946</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мальцев</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maltsev</surname><given-names>O V</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Вениаминович Мальцев – к. м. н., заместитель начальника кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний)</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, 4/2</p><p>+7 (921) 395-37-12)</p></bio><bio xml:lang="en"><p>Oleg V. Maltsev – Cand. Sci. (Med.) in medical science, deputy chief of infectious diseases department</p><p>St. Petersburg</p><p>+7 (921) 395-37-12</p></bio><email xlink:type="simple">olegdzein@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4398-7525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlov</surname><given-names>K V</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константин Вадимович Козлов – д. м. н., доцент, профессор кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний)</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, 4/2</p><p>+7 (921) 657-27-49</p></bio><bio xml:lang="en"><p>Konstantin V. Kozlov – Dr. Sci. (Med.), assistant professor of infectious diseases department</p><p>St. Petersburg</p><p>+7 (921) 657-27-49</p></bio><email xlink:type="simple">kosttiak@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жданов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhdanov</surname><given-names>K V</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константин Валерьевич Жданов – д. м. н., профессор, чл.-корр. РАН, начальник кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний) </p><p>194044, Санкт-Петербург, ул. Академика Лебедева, 4/2</p><p>+7 (921) 939-82-95</p></bio><bio xml:lang="en"><p>Konstantin V. Zhdanov – Dr. Sci. (Med.), professor, chief of infectious diseases department</p><p>St. Petersburg</p><p>+7 (921) 939-82-95</p></bio><email xlink:type="simple">zhdanovkv@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9154-7017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzin</surname><given-names>A A</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр Александрович Кузин – д. м. н., доцент, начальник кафедры (общей и военной эпидемиологии)</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, 4/2</p></bio><bio xml:lang="en"><p>Alexander A. Kuzin – Dr. Sci. (Med.), assistant professor, chief of infectious diseases department</p><p>St. Petersburg</p></bio><email xlink:type="simple">paster-spb@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7791-8993</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зобов</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Zobov</surname><given-names>A E</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Евгеньевич Зобов – к. м. н. преподаватель кафедры (общей и военной эпидемиологии)</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, 4/2</p><p>+7 (950) 031-84-26</p></bio><bio xml:lang="en"><p>Andrey E. Zobov – Dr. Sci. (Med.), Lieutenant Colonel of the Medical Service, Teacher of the Department (of General and Military Epidemiology)</p><p>SPIN-код: 4281-2680</p><p>AuthorID: 822170</p><p>St. Petersburg</p><p>+7 (950) 031-84-26</p></bio><email xlink:type="simple">dr.andrey98@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3165-968X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пузиков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Puzikov</surname><given-names>A V</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр Владимирович Пузиков – слушатель факультета подготовки врачей для сухопутных, ракетных и воздушно-десантных войск</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, 4/2</p><p>+7 (981) 781-59-46)</p></bio><bio xml:lang="en"><p>Alexander V. Puzikov – cadet of faculty of training doctors for missile, land and airborne forces</p><p>St. Petersburg</p><p>+7 (981) 781-59-46</p></bio><email xlink:type="simple">sashook007@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Военно-­медицинская академия имени С. М. Кирова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S. M. Kirov Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>03</month><year>2022</year></pub-date><volume>21</volume><issue>1</issue><fpage>67</fpage><lpage>73</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Касьяненко К.В., Мальцев О.В., Козлов К.В., Жданов К.В., Кузин А.А., Зобов А.Е., Пузиков А.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Касьяненко К.В., Мальцев О.В., Козлов К.В., Жданов К.В., Кузин А.А., Зобов А.Е., Пузиков А.В.</copyright-holder><copyright-holder xml:lang="en">Kasyanenko K.V., Maltsev O.V., Kozlov K.V., Zhdanov K.V., Kuzin A.A., Zobov A.E., Puzikov A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1463">https://www.epidemvac.ru/jour/article/view/1463</self-uri><abstract><p>Актуальность. Несмотря на реализацию мер по снижению заболеваемости и смертности среди медицинских работников, находящихся в контакте с пациентами, госпитализированными по поводу новой коронавирусной инфекции, вызванной SARS-CoV-2 (далее – COVID-19), их уровень на сегодняшний день остается высоким. Учитывая сложность достижения необходимого числа вакцинированных для формирования коллективного иммунитета, актуальным становится вопрос поиска дополнительных медикаментозных путей профилактики COVID-19, особенно в группах риска. Цель. Оценить влияние азоксимера бромида на число случаев подтвержденного заболевания COVID-19 среди медицинских работников, а также на уровень хронической усталости в исследуемых группах. Материалы и методы. В исследование были включены 78 человек мужского и женского пола. Опытную группу составил 41 человек, который принимали азоксимера бромид в течение 38 дней. Группу сравнения составили 37 человек, которым азоксимера бромид не назначался. Оценивалась эпидемиологическая эффективность препарата. Статистическая оценка значимости различий проводилась с использованием t-критерия Стьюдента, критерия χ2 Пирсона. Результаты. Число участников исследования, заболевших COVID-19, в опытной группе было достоверно ниже, чем в группе сравнения. Отмечена достоверно более быстрая редукция проявлений синдрома хронической усталости у участников исследования, принимавших азоксимера бромид. Нежелательных явлений во время приема исследуемого препарата участниками исследования отмечено не было. Выводы. Азоксимера бромид показал эпидемиологическую эффективность при применении у медицинских работников, непосредственно оказывающих медицинскую помощь пациентам с COVID-19 (при работе в «красной зоне»), в том числе способствуя более быстрой нормализации психологического состояния медицинских работников.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. Despite the implementation of measures to reduce morbidity and mortality among medical workers who are in contact with patients hospitalized for a new coronavirus infection caused by SARS-CoV-2 (hereinafter – COVID-19), their level remains high today. Given the difficulty of achieving the required number of vaccinated to form collective immunity, the issue of finding additional drug-based ways to prevent COVID-19, especially in risk groups, becomes urgent. Aims. To evaluate the effect of azoximer bromide on the number of cases of confirmed COVID-19 disease among medical workers, as well as on the level of chronic fatigue in the study groups. Materials and methods: 78 men and women were included in the study. The experimental group consisted of 41 people who took azoximer bromide for 38 days. The comparison group consisted of 37 people who were not prescribed azoximer bromide. The epidemiological efficacy of the drug was evaluated. Statistical evaluation of the significance of the differences was carried out using the Student's t-test, Pearson's criterion χ2. Results. The number of study participants with COVID-19 in the experimental group was significantly lower than in the comparison group. A significantly faster reduction of manifestations of chronic fatigue syndrome was noted in study participants who took azoximer bromide. There were no adverse events during the administration of the studied drug by the study participants. Conclusions. Azoximer bromide has shown epidemiological efficacy when used by medical workers directly providing medical care to patients with COVID-19 (when working in the «red zone»), including contributing to the more rapid normalization of the psychological state of medical workers</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>профилактика</kwd><kwd>азоксимера бромид</kwd><kwd>новая коронавирусная инфекция</kwd><kwd>медицинские работники</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>prophylaxis</kwd><kwd>azoximer bromide</kwd><kwd>healthcare workers No conflict of interest to declare</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Coronavirus disease (COVID-19) Weekly situational report. World Health Organization. Доступно на: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Coronavirus disease (COVID-19) [Internet]. Weekly situational report. Available at: https://www.who.int/emergencies/diseases/novel-coronavi-rus-2019/situation-reports.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.</mixed-citation><mixed-citation xml:lang="en">Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;23(11):1061–1069. doi:10.1001/jama.2020.1585</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции (COVID-19) Министерства здравоохранения Российской Федерации. Доступно на: http://static0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v10.pdf.</mixed-citation><mixed-citation xml:lang="en">Ministry of healthcare of the Russian Federation. Vremennye metodicheskie rekomendacii po profilaktike, diagnostike i lecheniyu novoj koronavirusnoj infekcii (COVID-19). Avail- able at: http://static0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v10.pdf. Ссылка активна на 05.08.2021. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Galvis V, Spinelli FR, Tello A, Sossa CL, Higuera JD, Go´mez ED, et al. Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials. Доступно на: https://europepmc.org/article/med/ 32571633.</mixed-citation><mixed-citation xml:lang="en">Galvis V., Spinelli FR., Tello A., et al. Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials. Archivos De Bronconeumo- logia. 2020;56(9):606–608. doi:10.1016/j.arbres.2020.05.008</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in suppression of previous advisory date 23rd March, 2020). Ministry of Health and Family Welfare. Доступно на: https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf.</mixed-citation><mixed-citation xml:lang="en">Mukhopadhyay S., Suhrita P., Basabdatta S. Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India. Perspectives in clinical research. 2021;12(1):58–59. doi:10.4103/picr.PICR_310_20</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Coronavirus disease (COVID-19): Hydroxychloroquine. World Health Organisation; Доступно на: https://www.who.int/news-room/q-a-detail/coronavirus-diseasecovid-19-hydroxychloroquine.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Coronavirus disease (COVID-19): Hydroxychloroquine. Available at: https://www.who.int/news-room/q-a-detail/coronavirus-diseasecovid-19-hydroxychloroquine.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-19 treatment guidelines. Ivermectin. National Institutes of health. Доступно на: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/.</mixed-citation><mixed-citation xml:lang="en">Bryant A., Lawrie TA., Dowswell T. et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American journal of therapeutics. 2021;28(4):434–460. doi:10.1097/MJT.0000000000001402</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации по лекарственной терапии острых респираторных вирусных инфекций (ОРВИ) в амбулаторной практике в период эпидемии COVID-19 (версия 2Б 16.04.2020) Министерства здравоохранения Российской Федерации. Доступно на: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf.</mixed-citation><mixed-citation xml:lang="en">Ministry of health of the Russian Federation. Vremennye metodicheskie rekomendacii po lekarstvennoj terapii ostryh respiratornyh virusnyh infekcij (ORVI) v ambulatornoj praktike v period epidemii COVID-19 (versiya 2B 16.04.2020). Available at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Оценка рисков контакта с вирусом COVID-19 для медицинских работников и ведение контактировавших: временное руководство от 4 марта 2020 г. Режим доступа: https://apps.who.int/iris/handle/10665/331725.</mixed-citation><mixed-citation xml:lang="en">World Health organization. Ocenka riskov kontakta s virusom COVID-19 dlya medicinskih rabotnikov i vedenie kontaktirovavshih: vremennoe rukovodstvo ot 4 marta 2020 g. Available at: https://apps.who.int/iris/handle/10665/331725. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sant’Ana G, Imoto AM, Amorim FF, Taminato M, Peccin MS, Santana LA, et al. Infection and death in healthcare workers due to COVID-19: a systematic review. Acta Paul Enferm. 2020; eAPE20200107. DOI: 10.37689/acta-ape/2020AO0107.</mixed-citation><mixed-citation xml:lang="en">Sant’Ana G., Imoto AM., Amorim FF., et al. Infection and death in healthcare workers due to COVID-19: a systematic review. ACTA Paulista de enfermagem. 2020;34. doi:10.37689/acta-ape/2020AO0107.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kostinov M.P., Akhmatova N.K., Khromova E.A., Skhodova S.A., Stolpnikova V.N., Cherdantsev A.P., et al. The impact of adjuvanted and non-adjuvanted influenza vaccines on the innate and adaptive immunity effectors. IntechOpen book series. Infectious diseases, volume 1. Influenza. Therapeutics and challenges. Edited by Shailendra K. Saxena–2018. Chapter 5:83–109. http://dx.doi.org/10.5772/intechopen.71939.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P., Akhmatova N.K., Khromova E.A., et al. The impact of adjuvanted and non-adjuvanted influenza vaccines on the innate and adaptive immunity effectors. In: Influenza – therapeutics and challenges. London: IntechOpen book series; 2018:83–109.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Вавилова В. П., Вавилов А. М., Перевощикова Н. К., Царькова С.А., Пивовар О. И., Климова И. И. Опыт профилактики новой коронавирусной инфекции (COVID-19) у медицинских работников. Терапия. 2020. – № 6. – С. 93 – 102.</mixed-citation><mixed-citation xml:lang="en">Vavilova V.P., Vavilov A.M., Perevoshikova N.K., et al. Opyt profilaktiki novoj koronavirusnoj infekcii (COVID-19) u medicinskih rabotnikov. Terapiya. 2020;6:93–02. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Лусс Л. В., Некрасов А. В., Пучкова Н. Г. и др. Роль иммуномодулирующей терапии в общеклинической практике. Иммунология. 2000. – №5. – С. 34–38.</mixed-citation><mixed-citation xml:lang="en">Luss L. V., Nekrasov A. V., Puchkova N. G. et al. Rol’ immunomoduliruyushchej terapii v obshcheklinicheskoj praktike. Immunologiya. 2000;5:34–38. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Szemiel AM, Merits A, Orton RJ, MacLean OA, Pinto RM, Wickenhagen A, et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 2021;17;17(9). doi: 10.1371/journal.ppat.1009929.</mixed-citation><mixed-citation xml:lang="en">Szemiel AM., Merits A., Orton RJ., et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathogens. 2021;17(9). doi: 10.1371/journal.ppat.1009929.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Grossi G, Perski A, Evengard B, Blomkvist V, Orth-Gomer K. Physiological correlates of burnout among women. J Psycho Res. 2003;55:309–316. doi: 10.1016/S00223999(02)00633-5.</mixed-citation><mixed-citation xml:lang="en">Grossi G., Perski A., Evengard B., et al. Physiological correlates of burnout among women. Journal of Psychosomatic Research. 2003;55:309–316. doi: 10.1016/S0022-3999(02)00633-5.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Casado A, De Lucas N, Lopez-Fernandez E, Sanchez A, Jimenez JA. Lipid peroxidation, occupational stress and aging in workers of a prehospital emergency service. Eur J Emerg Med. 2006;13:165–17. doi: 10.1097/01.mej.0000194404.61076.88.</mixed-citation><mixed-citation xml:lang="en">Casado A., De Lucas N., Lopez-Fernandez E., et al. Lipid peroxidation, occupational stress and aging in workers of a prehospital emergency service. European Journal of Emergency Medicine. 2006;13:165–170. doi: 10.1097/01.mej.0000194404.61076.88</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
